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Abstract: Research on the adenosine receptors has been supported by the continuous discovery of
new chemical probes characterized by more and more affinity and selectivity for the single adenosine
receptor subtypes (A1, A2A, A2B and A3 adenosine receptors). Furthermore, the development of new
techniques for the detection of G protein-coupled receptors (GPCR) requires new specific probes.
In fact, if in the past radioligands were the most important GPCR probes for detection, compound
screening and diagnostic purposes, nowadays, increasing importance is given to fluorescent and
covalent ligands. In fact, advances in techniques such as fluorescence resonance energy transfer
(FRET) and fluorescent polarization, as well as new applications in flow cytometry and different
fluorescence-based microscopic techniques, are at the origin of the extensive research of new fluorescent
ligands for these receptors. The resurgence of covalent ligands is due in part to a change in the
common thinking in the medicinal chemistry community that a covalent drug is necessarily more
toxic than a reversible one, and in part to the useful application of covalent ligands in GPCR structural
biology. In this review, an updated collection of available chemical probes targeting adenosine
receptors is reported.
Keywords: adenosine receptors; fluorescent ligands; radioligands; radiotracers; covalent ligands;
GPCR probes
1. Introduction
Since their discovery in the mid seventies [1,2], adenosine receptors (ARs) have attracted research
interest for their implication in a wide range of physiological and pathological processes (i.e., asthma,
ischemia, cancer, Parkinson’s disease, etc.) [3]. As a consequence, at the same time research commenced
on specific receptor probes that are essential tools for receptor characterization [4,5]. ARs exist as four
different subtypes: A1, A2A, A2B and A3 ARs [6,7]. Due to the advancement in techniques for detection
and characterization of receptors, and in particular of G protein-coupled receptors (GPCRs) [8–12],
the availability of suitable probes is a constant need. In particular, this review covers three specific
chemical probe families for ARs: radioactive, covalent and fluorescent ligands. Radioactive ligands,
properly called radioligands, are the oldest class of AR probes, and still represent the principal tool
in drug discovery since their use in binding assays [7]. Recently, the broad interest in radioactive
ligands is due to their development as radiotracers in positron emission tomography (PET), leading
to new diagnostic possibilities [13,14]. On the other hand, covalent ligands for GPCRs, which were
in the past used as tools to purify, isolate or pharmacologically characterize receptors, have recently
attracted the interest of the scientific community for their ability to stabilize their target protein,
increasing the probability of obtaining X-ray crystal structures [10]. This strategy was successfully
applied for the A1 AR subtype [15,16]. Since A2B and A3 AR crystal structures are still lacking, it is
easy to imagine that several works will focus on development of covalent ligands for these receptor
subtypes in the near future. Finally, the last few years have been characterized by the application of a
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variety of fluorescence-based methods for GPCR structure biology and drug discovery [17]. These
techniques involve the introduction of a fluorescent tag on a GPCR or on a GPCR ligand, leading to
fluorescent ligands, which are discussed here [9,18–20]. The aim of this review is to give a panorama
of the available chemical probes for the ARs to researchers working in this field or medicinal chemists
working on ARs or other GPCR targets.
2. Radioligands and Radiotracers
It is well known, that radioligand probes are useful for studying both the distribution and
functions of receptors. In this class of compounds, two families of derivatives should be considered:
i) radioligands, generally tritiated or iodinated, for binding studies; ii) radioligands used for imaging,
in general probes including isotopes such as 11C, 18F and 15O.
In the first class of compounds, in the last decades, several examples of radioligands for all
AR subtypes, both agonists and antagonists, with different degrees of potency and selectivity have
been reported and extensively reviewed [7,21–24]. Our purpose is to give a brief update of the work
developed in this field in this review.
Considering labeled derivatives for binding studies only an agonist for A2B AR named
[3H]-BAY60-6583 (1) was recently reported by the group of Prof. C.A. Müller (Figure 1) [25].
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Figure 1. Structure of BAY60-6583. 
This partial agonist in its tritiated form (the position of tritium is not reported) failed to be a 
good probe for binding studies. This is probably due to its moderate affinity at the human A2B 
receptor and high level of non-specific binding. The only results obtained using this radioligand 
indicate that nucleoside and non-nucleoside agonists most probably bind the receptor in different 
conformations [25].  
In contrast to the development of tritiated or 125I radioligands, in the last few years great efforts 
have been made in the field of radiotracers for imaging [14]. In particular, several examples of 11C or 
18F derivatives for the different AR subtypes have been reported. 
Regarding the 11C derivatives, some recent examples (compounds 2–5) have been reported in 
Figure 2, in particular, regarding the A1 and A2A ARs.  
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One of the most studied derivatives is xanthine derivative [1-methyl-11C]8-dicyclopropylmethyl-
1-methyl-3-propylxanthine (11C-MPDX, 2). This compound has been utilized for various studies [26–28].
For example, Paul and coworkers performed in vivo binding studies in rats hypothesizing that agonists
and antagonists may bind in different sites at the A1 receptor [26]. The same derivative was also utilized
to evaluate A1 AR alterations in patients with chronic diffuse axonal injury [27] or to investigate the
density of A1 ARs in patients with early-stage Parkinson’s disease [28].
Another interesting ligand for the A1 AR, is the pyridine derivative 3 reported by Guo et al. This
compound could be considered the first brain blood barrier (BBB)-permeable A1 partial agonist with
promising properties of detection of endogenous adenosine fluctuations [29].
Also in the field of A2A AR antagonists, some labeled compounds have been recently reported,
in particular the styryl-xanthine derivative [7-methyl-11C]-(E)-8-(3,4,5-trimethoxystyryl)-1,3,7-
trimethylxanthine (11C-TMSX, 4) that has been utilized for demonstrating that A2A receptors could be
a future target to enhance brown adipose tissue (BAT) metabolism [30]. In addition, the non-xanthine
Pharmaceuticals 2019, 12, 168 3 of 21
labeled derivative 11C-preladenant (5) has been reported to be an interesting probe for investigating
cerebral distribution of A2A ARs and other kinetic aspects such as its extensive distribution in the
striatum [31,32].Phar aceuticals 2019, 12, x FOR PEER REVIEW 3 of 21 
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Figure 2. Structures of 11C labeled adenosine receptor (AR) ligands. 
One of the most studied derivatives is xanthine derivative 
[1-methyl-11C]8-dicyclopropylmethyl-1-methyl-3-propylxanthine (11C-MPDX, 2). This compound 
has been utilized for various studies [26–28]. For example, Paul and coworkers performed in vivo 
binding studies in rats hypothesizing that agonists and antagonists may bind in different sites at the 
A1 receptor [26]. The same derivative was also utilized to evaluate A1 AR alterations in patients with 
chronic diffuse axonal injury [27] or to investigate the density of A1 ARs in patients with early-stage 
Parkinson’s disease [28]. 
Another interesting ligand for the A1 AR, is the pyridine derivative 3 reported by Guo et al. This 
compound could be considered the first brain blood barrier (BBB)-permeable A1 partial agonist with 
promising properties of detection of endogenous adenosine fluctuations [29]. 
Also in the field of A2A AR antagonists, some labeled compounds have been recently reported, 
in particular the styryl-xanthine derivative 
[7-methyl-11C]-(E)-8-(3,4,5-trimethoxystyryl)-1,3,7-trimethylxanthine (11C-TMSX, 4) that has been 
utilized for demonstrating that A2A receptors could be a future target to enhance brown adipose 
tissue (BAT) metabolism [30]. In addition, the non-xanthine labeled derivative 11C-preladenant (5) 
has been reported to be an interesting probe for investigating cerebral distribution of A2A ARs and 
other kinetic aspects such as its extensive distribution in the striatum [31,32]. 
Nevertheless, one of the major problems of the use of 11C-labeled compounds is the short 
half-life of this isotope (20 min), this means that the compound has to be prepared and immediately 
utilized before its inactivation. For this reason, other isotopes are preferred to 11C such as 18F, which 
has a half-life of 109 min. In this field, some promising agents for A1, A2B and A3 receptors (6–10) 
have been reported (Figure 3). 
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One of the most used 18F-labeled compounds could be considered to be the xanthine derivative 
18F-8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine (18F-CPFPX, 6). This compound has been 
extensively used for developing suitable pharmacokinetic models for the quantification of cerebral 
A1 ARs [33]. 
It has also been utilized to visualize and quantify the in vivo occupancy of the human cerebral 
adenosine A1 receptor by caffeine [34], and demonstrated that its chronic use did not lead to 
persistent changes in functional availability of A1 ARs [35]. 
Taking into account the results obtained with these derivatives, Kreft and coworkers developed 
other 18F-CPFPX structurally-related derivatives named CBCPM 
(8-cyclobutyl-1-cyclopropymethyl-3-(3-fluoropropyl)xanthine, 7) and CPMMCB 
(1-cyclopropylmethyl-3-(3-fluoropropyl)-8-(1-methylcyclobutyl)xanthine, 8), respectively, which 
showed similar behavior to the reference compound in preliminary PET studies [36]. 
In addition, a promising labeled derivative, named 18F-FE@SUPPY 
(5-(2-fluoroethyl)2,4-diethyl-3-(ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate, 9), has been 
developed for the A3 AR, which has been shown to be a tracer for studying pharmacokinetic aspects 
and mapping A3 ARs in rats [37,38]. 
Very recently, a 18F-labeled form of a pyrazine A2B AR antagonists (10) has been reported by 
Lindemann et al. [39]. Preliminary studies on this compound, which showed binding affinity in the 
nanomolar range towards the human A2B AR, clearly indicated the potential of this derivative as a 
tracer for studying this receptor subtype and provided an important basis for the development of 
new tracers for A2B AR [39]. 
3. Covalent Ligands 
It is well known that covalent ligands may be considered important pharmacological tools for 
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It has also been utilized to visualize and quantify the in vivo occupancy of the human cerebral
adenosine A1 receptor by caffeine [34], and demonstrated that its chronic use did not lead to persistent
changes in functional availability of A1 ARs [35].
Taking into account the results obtained with these derivatives, Kreft and coworkers developed
other 18F-CPFPX structurally-related derivatives named CBCPM (8-cyclobutyl-1-cyclopropymethyl-3-
(3-fluoropropyl)xanthine, 7) and CPMMCB (1-cyclopropylmethyl-3-(3-fluoropropyl)-8-(1-methylcyclobutyl)
xanthine, 8), respectively, which showed similar behavior to the reference compound in preliminary
PET studies [36].
In addition, a promising labeled derivative, named 18F-FE@SUPPY (5-(2-fluoroethyl)2,4-diethyl-3-
(ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate, 9), has been developed for the A3 AR, which
has been shown to be a tracer for studying pharmacokinetic aspects and mapping A3 ARs in rats [37,38].
Very recently, a 18F-labeled form of a pyrazine A2B AR antagonists (10) has been reported by
Lindemann et al. [39]. Preliminary studies on this compound, which showed binding affinity in the
nanomolar range towards the human A2B AR, clearly indicated the potential of this derivative as a
tracer for studying this receptor subtype and provided an important basis for the development of new
tracers for A2B AR [39].
3. Covalent Ligands
It is well known that covalent ligands may be considered important pharmacological tools for the
study of the receptors; in fact, the irreversible blockade of the receptors could reveal details of both
structural binding interactions and the patho-physiological role of the examined receptor.
The strategy utilized for obtaining irreversible ligands is generally based on the introduction of
chemoreactive moieties on the scaffold of well-known agonists and/or antagonists. The limiting step in
preparing this kind of probe is the position on which the chemoreactive group should be introduced in
order to obtain irreversible block of the receptor without losing both affinity and selectivity. For this
reason, several structure–activity relationship studies (SAR) have been performed in order to optimize
the structural requirements that are indispensable for obtaining irreversible probes that retain affinity
and selectivity.
In the field of ARs, several examples of covalent agonists and antagonists have been reported in the
last decades. We wish, for this reason, to briefly summarize the results obtained in this research area.
Regarding agonists for ARs, several examples of A1, A2A and A3 receptor subtypes are reported
and depicted in Figures 4 and 5.
The strategy to obtain irreversible agonists for ARs is based on the core modification of the natural
nucleoside adenosine.
Concerning the A1 AR subtype, examples of covalent agents are reported and summarized in
Figure 4 [40–42].
In particular the N6 substituted derivative of adenosine, named m-DITC-ADAC
(4-isothiocyanatophenylaminothiocarbonyl, DITC; adenosine amine congener or N6-[4-[[[4-[[[(2-
Aminoethyl)amino]carbonyl]methyl]-anilino]carbonyl]methyl]phenyl]adenosine, ADAC) (11), proved
to be a good irreversible agonist for A1 AR. It was able to mimic ischemic preconditioning in rabbits [40]
and also prolong the stimulus of the His bundle (SA) interval by 2.1 fold in guinea pig isolated
hearts [41].
Another interesting covalent agonist, R-AHPIA (2-azido-N-(2-(4-hydroxyphenyl)-1-methylethyl)-
adenosine, 12) was reported by Klotz and coworkers [42]. This ligand was also labeled with 125I and,
after UV irradiation, it irreversibly binds to the rat receptor, which was isolated for the first time as a
protein of about 35 KDa [42].
A quite extensive SAR study on the adenosine nucleus for obtaining other covalent ligands for
human ARs was performed by Jorg and coworkers [16], who obtained a series of compounds of
general formula 13. Nevertheless no extensive pharmacological studies for their characterization were
reported [16].
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Development of covalent A2A agonists was performed by an extensive SAR study on the GS21680
(2-p-(2-carboxyethyl)phenethylamino-5′-N-ethylcarboxamidoadenosine) scaffold, by introduction of
several chemoreactive groups on its carboxylic acid moiety (Figure 5) [24,43,44].
These studies led to the discovery of a compound named DITC-APEC (2-[(2-aminoethyl-
aminocarbonylethyl)phenylethylamino]-5’-N-ethyl-carboxamidoadenosine, APEC) (14), which was
able to induce concentration dependent coronary vasodilation that persisted for a long time, even
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after washout. This suggests that compound 14 irreversibly bound A2A AR in guinea pig coronary
arteries [44].
A quite similar compound (15) was obtained by introducing a reactive ester on the CGS21680
nucleus as an acylating agent. This derivative was found to be an irreversible agonist for the human
A2A AR, and docking studies suggested that two lysine residues in the second extracellular loop were
involved in the covalent binding. In fact, site directed mutagenesis studies confirmed that lysine 153
reacts with the active ester moiety, giving the irreversible adduct [45].
For the rat A3 AR subtype, an irreversible agonist (16) was developed by introducing a
benzyl-isothiocyanate group at the N6 position of 5’-(N-methylcarboxamido)adenosine, but, except
for binding experiments confirming the irreversible properties of the compound, no significative
pharmacological experiments were performed [46].
In addition, several irreversible antagonists for ARs have been reported. We could classify the
obtained compounds in two major classes: i) xanthine derivatives (the natural antagonists for ARs),
and ii) non-xanthine derivatives.
In the xanthine group, several derivatives of the well-known A1 AR antagonist DPCPX
(1, 3-dipropyl-8-cyclopentyl xanthine) have been synthesized by introducing chemoreactive
groups [47–49]. Among this large number of synthesized compounds, the most interesting derivative
could be considered to be 8-cyclopentyl-3-N-[3-((3-(4-fluorosulphonyl)benzoyl)-oxy)-propyl]-1-
N-propyl-xanthine (FSCPX, 17), which proved to be the best irreversible rat A1 AR antagonist
reported [47] (Figure 6).
Pharmaceuticals 2019, 12, x FOR PEER REVIEW 7 of 21 
 
utilized to obtain a co-crystalized structure of the human A1 AR. With the help of computational and 
mutational studies, the structural basis for subtype selectivity versus A2A subtype were identified 
[15]. 
A quite similar approach for developing other A1 adenosine covalent antagonists has been 
utilized using XAC, 
(N-(2-aminoethyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-acetamid
e), as a template. This approach led to the discovery of several promising covalent agents such as 
m-DITC-XAC (19), p-DITC-XAC (20) [52], and the trifunctionalized compound 21 [53], which were 
found to be irreversible ligands for rat A1 ARs in binding studies. In particular, compound 21 was 
found to be 894-fold selective for A1 vs. A2A ARs (Figure 6) [53].  
N
N N
NnC3H7
O
O H
O
O
SO2F
FSCPX, 17
N
N N
NnC3H7
O
O H
HN
O
SO2F
DU172, 18
N
N N
NnC3H7
nC3H7
O
O H
O
HN
NH
NHR
O
S
NCS
NCS
NCS
NCS
R =
R =
R =
p-DITC-XAC, 20
m-DITC-XAC, 19
21
N
N N
NH3C
CH3
O
O CH3
NCS
ISC, 22  
Figure 6. Structures of xanthine derivatives as covalent antagonists for ARs. 
By modifying the xanthine nucleus, other chemical entities have been developed by Scammells 
and coworkers. These studies led to some quite interesting covalent antagonists towards hamster 
receptors but low pharmacological characterization was reported [54]. 
In this field, some styrylxanthines have been investigated with the aim to obtain novel 
irreversible A2A AR antagonists. These studies led to the discovery of ISC 
(8-(3-isothiocyanatostyryl)caffeine, 22), which in binding studies was found to be a good covalent 
ligand at the rat receptor, with potency in the nanomolar range and good levels of selectivity (Figure 
6) [55]. 
Figure 6. Structures of xanthine eri ati es as covalent antagonists for ARs.
Pharmaceuticals 2019, 12, 168 7 of 21
Several pharmacological studies have been performed using FSCPX (17) as a probe, permitting
better understanding of the pathophysiological role of the A1 AR [50,51].
A structurally related derivative to FSCPX (17), bearing a cyclohexyl group at the 8 position and
an amido function instead of an ester at the 3 position, named DU172 (18), has been synthesized and
utilized to obtain a co-crystalized structure of the human A1 AR. With the help of computational and
mutational studies, the structural basis for subtype selectivity versus A2A subtype were identified [15].
A quite similar approach for developing other A1 adenosine covalent antagonists has been utilized
using XAC, (N-(2-aminoethyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-
acetamide), as a template. This approach led to the discovery of several promising covalent agents
such as m-DITC-XAC (19), p-DITC-XAC (20) [52], and the trifunctionalized compound 21 [53], which
were found to be irreversible ligands for rat A1 ARs in binding studies. In particular, compound 21
was found to be 894-fold selective for A1 vs. A2A ARs (Figure 6) [53].
By modifying the xanthine nucleus, other chemical entities have been developed by Scammells
and coworkers. These studies led to some quite interesting covalent antagonists towards hamster
receptors but low pharmacological characterization was reported [54].
In this field, some styrylxanthines have been investigated with the aim to obtain novel irreversible
A2A AR antagonists. These studies led to the discovery of ISC (8-(3-isothiocyanatostyryl)caffeine, 22),
which in binding studies was found to be a good covalent ligand at the rat receptor, with potency in
the nanomolar range and good levels of selectivity (Figure 6) [55].
Also in the non-xanthine family, several examples of irreversible AR antagonists have been
reported [56–59].
In order to obtain covalent A2A antagonists, insertion of a fluorosulfonyl moiety on the well-known
A2A AR antagonists SCH58261 (2-(2-Furanyl)-7-(2-phenylethyl)-7H-pyrazolo [4,3-e][1,2,4]triazolo[1,5-c]
pyrimidin-5-amine) and ZM241385 (4-(2-(7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
ylamino)ethyl)phenol) have been developed. This approach led to the discovery of FSPTP (5-amino-7-
[2-(4-fluorosulfonyl)phenylethyl]-2-(2-furyl)-pryazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine, 23) and
LUF7445 ((4-((3-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino)propyl)carbamoyl)
benzene sulfonyl fluoride), 24) as irreversible A2A AR antagonists (Figure 7).
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The use of FSPTP (23) in pharmacological studies showed that there is a large receptor reserve 
for the A2A AR, which mediates the increase in coronary conductance in guinea pigs [56], while 
LUF7445 (24), through the help of computational and mutational studies permitted identification of 
lysine 153 as the amino acid involved in covalent binding at the hA2A AR [58]. 
A quite similar approach has been utilized for developing covalent human A3 AR antagonists, 
leading to a derivative named LUF7602 
(4-((3(8-methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f]purin-1(2H)yl)propyl)carbamoyl)benz
enesulfonyl fluoride, 25) [57] and a pyrazolo-triazolo-pyrimidine compound (26) [59]. The first one 
showed that tyrosine 265 was involved in the covalent binding, while compound 26, through the 
help of computational studies, suggested that serine 247 or cysteine 251, both in TM6, could be 
responsible for covalent binding. Of course, these results clearly indicate that the two compounds 
have a different binding pose into the receptor binding site. 
4. Fluorescent Ligands  
The concept of using fluorescent ligands to detect GPCRs in native conditions, including ARs, is 
not new [60]. However, the urgent need for new fluorescent tools for ARs is given by the possibility 
of applying new fluorescent techniques to deeply study the receptors in cells, in particular, receptor 
localization, both on the membrane surface and during their internalization. This would allow for 
study of desensitization, recycling and homo- or oligo-merization of the receptors [19]. A description 
of the techniques used to study GPCRs was recently reviewed and comprised fluorescence 
.
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The use of FSPTP (23) in pharmacological studies showed that there is a large receptor reserve for
the A2A AR, which mediates the increase in coronary conductance in guinea pigs [56], while LUF7445
(24), through the help of computational and mutational studies permitted identification of lysine 153
as the amino acid involved in covalent binding at the hA2A AR [58].
A quite similar approach has been utilized for developing covalent human A3 AR antagonists,
leading to a derivative named LUF7602 (4-((3(8-methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido
[2,1-f ]purin-1(2H)yl)propyl)carbamoyl)benzenesulfonyl fluoride, 25) [57] and a pyrazolo-triazolo-
pyrimidine compound (26) [59]. The first one showed that tyrosine 265 was involved in the covalent
binding, while compound 26, through the help of computational studies, suggested that serine 247 or
cysteine 251, both in TM6, could be responsible for covalent binding. Of course, these results clearly
indicate that the two compounds have a different binding pose into the receptor binding site.
4. Fluorescent Ligands
The concept of using fluorescent ligands to detect GPCRs in native conditions, including ARs,
is not new [60]. However, the urgent need for new fluorescent tools for ARs is given by the
possibility of applying new fluorescent techniques to deeply study the receptors in cells, in particular,
receptor localization, both on the membrane surface and during their internalization. This would
allow for study of desensitization, recycling and homo- or oligo-merization of the receptors [19].
A description of the techniques used to study GPCRs was recently reviewed and comprised fluorescence
polarization, confocal microscopy, fluorescence correlation spectroscopy (FCS), flow cytometry, FRET
and bioluminescence resonance energy transfer (BRET) [18,19,61–63]. Nowadays, thanks to the
progress in both synthetic and instrumental techniques, a plethora of fluorophores is available,
with a diversity of applicable conjugation strategies that simplify the development of new specific
fluorescent ligands [64–66]. In fact, the literature reports several examples of fluorescent ligands for
all four AR subtypes. A very comprehensive review on fluorescent ligands for ARs was reported by
Kozma et al. [67] and extended to some newer derivatives by another two reviews published in 2014
and 2015 [68,69]. Thus, here the most representative fluorescent ligands are reported among with the
new fluorescent ligands for the ARs reported in the literature from 2015 to now.
The first fluorescent ligands were developed in 1987 by Jacobson and coworkers to target the rat A1
AR. The authors conjugated the fluorophores fluorescein isothiocyanate (FITC) and nitrobenzoxadiazole
(NBD) to the free amino group of the A1 agonist ADAC (FITC-ADAC, 27; NBD-ADAC, 28), maintaining
affinity to the receptor (pKi@ratA1 = 8.14, 27; pKi@ratA1 = 8.36, 28). The same approach was used for
conjugating FITC to the A1 antagonist XAC, FITC-XAC (29, pKi@ratA1 = 6.90) (Figure 8) [60].
Therefore, fluorescent ligands for human adenosine receptors were developed both from agonists
and antagonists. Concerning agonists, only few derivatizations were made from the simple adenosine
scaffold. Specifically, in ABA-X-BY630 (30) [70], adenosine was conjugated by a linker at the 6 position,
while in compound 31 [71], thioadenosine was used to introduce the BODIPY (boron dipyrromethene)
fluorophore at the 2 position of the purine ring (Figure 9). ABA-X-BY630 (30) was developed as an
A1 ligand (pKi = 6.65), but compound 31 exhibited a preferential affinity towards the A3 AR subtype
(pKi = 6.21), showing more than ten-fold selectivity against A1 and A2A ARs. More efforts were made
with the more active, but still not selective, agonist NECA (5’-(N-ethylcarboxamido)adenosine). It has
been studied by different groups, where all substitutions were carried out at the 6 position and linkers
of different length were used, as were different fluorophores such as dansyl, NBD, BODIPY 630/650,
Cy5, Texas Red, and EvoBlue30 [70,72–75]. In most cases, the introduction of a fluorophore led to
A1 AR ligands. Macchia et al. developed a series of dansyl-NECA derivatives that exhibited higher
affinity at the A1 AR (i.e., ABEA-dansyl, 32) [75]. Because dansyl excitation wavelength (340 nm) falls
in the autofluorescence spectrum of cells and tissues, the authors substituted the dansyl group with a
longer excitation wavelength fluorophore such as NBD (λex = 465 nm, λem = 535 nm). Interestingly,
NBD led to a detrimental effect on A1 AR, while the affinity towards A3 AR (i.e., NBD-NECA, 33)
increased [73] (Figure 9).
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In contrast, Middleton et al. developed various NECA-BODIPY 630/650 derivatives as A1 ligands,
because red-emitting BODIPY fluorophores become brighter in non-aqueous environments, therefore
specific fluorescence on the plasma membrane surface can be more easily visualized. Among them,
ABEA-X-BY630 (34) showed high affinity for both A1 and A3 ARs and maintained agonist behavior [70]
(Figure 9). This allowed visualization of the receptors at the cell membrane by confocal microscopy
and quantification of its binding kinetics. Consequently, it was used as a probe to investigate allosteric
interactions given by small molecules and receptor dimerization [76,77]. Unfortunately, ABEA-X-BY630
(34) showed high levels of non-specific cytoplasmic uptake, which prevented its use in long-term
studies. In a w rk imed to impr ve these poor imaging prop rties, an additional tripepti e linker,
A-A-G, was introduced between the fluorophore and the agonist to obtai ABEA-A-A-G-X-BY630. All
four pos ible combinations of L and D amino acids were examined, and apart from the (L)A-(L)A-G
isomer, all others showed excellen affinity values at the A1 and A3 R. The ABEA-(D)A-(D)A-G-BY630
(35) gonist was selected for furth r experiments and because it showed activation of the Gs protei at
the A1 AR when tested at h gh concentrations, this compound was preferentially us d as a pr be for the
A3 AR (Figure 9). As an example, compound 35 was successfully used to investigate the internalization
process of A3 ARs and their co-localization with arrestin [78].
As shown in Figure 10, among agonists, the only other compound that was conjugated to
a fluorophore in order to obtain, in this case, an agonist for the A2A AR subtype was APEC
(2-[2-[4-[2-(2-aminoethylcarbonyl)ethyl]phenyl]ethylamino]-5′-N-ethylcarboxamidoadenosine). It
was successfully functionalized with FITC, Alexa Fluor 488 (MRS5206, 36) and Alexa Fluor 532
(MRS5424, 37) [79–81]. MRS5206 (36) showed affinity towards both A2A (Ki = 149 nM) and A3 (Ki =
240 nM) ARs and was used to demonstrate that A2A agonist-induced internalization is mediated by
a clathrin-dependent mechanism [80]. Instead, the APEC–Alexa Fluor 532 conjugate MRS5424 (37)
was developed to be applied in FRET experiments. In fact, the A2A receptor tagged with CFP (cyan
fluorescent protein) was able to emit at 480 nm when excited at about 430 nm (blue). Then, emission at
480 nm was able to excite Alexa Fluor 532 in MRS5424 (37), which consequently emitted at 554 nm
(yellow). In particular, MRS5424 (37) was used for the investigation of allosterism mediated by A2A/D2
oligomerization [8,81].
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APEC was also used to develop quantum dot (QD) conjugates, which are well-known for their
emission properties. In particular, a QD was functionalized, through a linker based on (R)-thioctic acid,
with a dendron containing multiple molecules of APEC. Dendron was used to increase the solubility of
the structure and to ensure a good loading of APEC on the QD. One of the prepared systems, MRS5303,
showed affinity towards A2A AR, but further work is needed to obtain a good A2A probe [82].
Finally, Jacobson and coworkers reported different methanocarba derivative-based fluorescent
probes for the A3 AR subtype. The functionalized scaffold is that of the A3 agonist MRS3558 ((1S,2R,3S,
4R,5S)-4-[2-chloro-6-[(3-chlorophenyl)methylamino]purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]
hexane-1-carboxamide) in which the chlorine atom at the 2 position of the purine ring was substituted
with an alkyne moiety, and where different fluorophores (e.g., Cy5, squaraine-rotaxane, Alexa Fluor
488, pyrene) were attached directly or through a linker [83–85]. Compound MRS5218 (38) is a full
agonist of the A3 AR, displaying an IC50 of 1.09 nM in a functional cAMP assay (Figure 10) [83].
Concerning antagonists, the most studied fluorescent probes were based on the xanthine derivative
XAC. As for NECA, several linkers and different fluorophores were introduced on the free amino
group in XAC in this case, leading to both A1 and A3 AR fluorescent antagonists [60,72,86–89]. Among
them XAC-X-BY630 (39) and CA200645 (40) are the more representative (Figure 11) [87,90].
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The first aim was to l t e 1 AR, and from SAR analy is, t is known that
the introduction of long chains at the 8 position of the xanthine ring are well tolerated by the A1 AR.
In fact, XAC-X-BY630 (39) showed affinity in the nanomolar range towards A1 AR and it was used to
quantify ligand-receptor binding at a single cell level using FCS [87]. Instead, CA200645 (40), which
bears a longer polyamido linker even if it is particularly used as an A3 florescent probe (i.e., for kinetics,
allosterism and dimerization studies by FCS and nano-BRET technology [91–93]), binds potently both
to A1 and A3 ARs, in fact, it was used in a high-content screening assay for both receptors [90].
Further optimization on the linker of XAC/BODIPY 630 derivatives was reported by Vernall et al.,
where, like NECA derivatives, the authors decided to introduce a peptide linker, instead of a naked
polyamido chain like in CA200645 (40) [89]. The aim was to increase selectivity at the A3 AR by
gaining specific interactions with the linker. In order to find a less expensive way to assess the SAR
of this compound, the BODIPY 630 was replaced by the similarly bulky Fmoc group. The linker
was made by two amino acids chosen between alanine, tyrosine, serine and asparagine. The last
were chosen for their polarity and, thus, ability to make hydrogen bonds. In addition, tyrosine can
also be engaged in pi-pi interactions. The best results were obtained with XAC-(S)-S-(S)-Y-BY630
(41), which showed a pKD of 9.12 towards the A3 AR, compared to a pKD of 7.26 towards the A1
AR [89]. Compound 41 demonstrated a long residence time at A3 AR (RT = 288 min); thus, when
it was used to determine the association and dissociation constants of the ligands, it gave quite
different constants with respect to those determined with classical radioligands, such as [3H]PSB-11
Pharmaceuticals 2019, 12, 168 13 of 21
([3H]-(8R)-8-ethyl-1,4,7,8-tetrahydro-4-5H-imidazo[2,1-i]purin-5-one) [92]. This result suggested again
that a probe should be properly selected before its use in an experiment.
XAC was also used to prepare GPCR ligand–dendrimer (GLiDe) conjugates. In particular, XAC
was functionalized at the free amino group present at the 8 position, with an alkyne-containing chain.
Alkyne was then used to perform a copper catalyzed click reaction with an azido-containing G4
(fourth-generation) polyamidoamine (PAMAM) dendrimer to form triazoles. Dendrimers were also
conjugated to fluorophores such as Alexa Fluor 488, leading to fluorescent dendrimers MRS5397 and
MRS5399. In addition, near infrared dyes were also used by Jacobson and coworkers, leading to
MRS5421 (which used NIR dye 800) and MRS5422 (which used NIR dye 700). These compounds
showed higher affinity towards the A2A AR, followed by A3 and A1 ARs [88].
A series of xanthine derivatives was recently developed to obtain fluorescent antagonists towards
the A2B AR [94]. The xanthine scaffold was chosen on the basis of known SAR for this receptor, which
suggested that 3-unsubstituted 8-phenyl-1-propylxanthine derivatives are generally more potent and
selective to A2B AR than the corresponding 1,3-substituted derivatives. Thus, the BODIPY fluorophore
was conjugated to the 8-phenyl by means of spacers of different lengths. The best compound of the
series was PSB-12105 (42) (Figure 12), which showed nanomolar or subnanomolar affinity towards
human, rat and mice receptors and was consequently used to develop a binding assay using flow
cytometry [94].
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I iti , scaffolds other than xanthines have been used to dev lop fluoresc nt ant gonists for
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for the various AR subtypes were used; among them can find [1,2,4]triazolo[1,5-c]quinazoli es [95],
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and benzo[4,5]imidazo[2,1-c][ ,2,4]triazines [101].
CGS15943 (9-chloro-2-(2-furanyl)-[ ,2,4]triazolo[1,5-c]quinazolin-5-amine) is a well-known
non-selective AR antagonist that, when conjugated to Alexa Fluor 488 by a triazole-containing
linker at the 5 position, led to MRS5449 (43, Figure 13) displaying a radioligand binding Ki value of 6.4
nM at the A3 AR, and was more than 10-fold selective against A1 and A2A ARs. For these characteristics
it was chosen for the establishment of an A3 AR biding assay using flow cytometry [95].
In contrast, the analog pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivative SCH442416
(5-Amino-7-[3-(4-methoxy)phenylpropyl]-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine),
was used to design potent A2A AR fluorescent antagonists. Linkers were introduced on the hydroxy
group on the phenylalkyl chain present at the 7 position of the scaffold. Three different fluorophores
were introduced: Alexa Fluor 488, Tamra and BODIPY 650/665, leading to MRS5346 (44), MRS5347 (45)
and MRS5418 (46), respectively (Figure 13). MRS5418 (46) showed the best affinity (Ki = 15.1 nM) and
selectivity for the A2A AR [97,98], but MRS5346 (44) was used in a fluorescence polarization-based
receptor binding assay at the A2A AR [99]. Ciruela and coworkers developed another member of this
class of A2A antagonists, where they introduced dye 467 directly to the hydroxyl group of SCH442416
(Figure 13). SCH442416Dy647 (47) was employed to undoubtedly demonstrate the presence of A2A/D2
oligomers in native tissues of rat striatum, which is essential information for designing new therapies
for Parkinson’s disease [69,100].
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The pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold was also functionalized at the 5 position,
leaving the 7 position unsubstituted and inserting a methyl group at the 8 position: substitutions that
should shift selectivity towards the A3 AR [102]. FITC was used as fluorophore and simple diamino
alkyl or PEG linkers were used as spacers. These derivatives exhibited equal low micromolar affinity
for the A2A and A3 AR subtypes [99]. In an attempt to obtain more potent derivatives, an aromatic ring,
which could gain some interactions with the receptor, was introduced. As expected, new compounds
(48 and 49) displayed nanomolar affinity at the two receptors (Ki A2A = 60.4 nM, Ki A3 = 73.6 nM, 48;
Ki A2A = 90 nM, Ki A3 = 31.8 nM, 49) (Figure 13) [103].
Vernall et al. developed a series of A3 fluorescent derivatives of the 4-amino-2-(4-methoxyphenyl)-
[1,2,4]triazolo[4,3-a]quinoxalin-1(2H)-one, by introducing different fluorophores through a polyamido
linker at the 4 position of the scaffold [96]. The presence of the p-methoxy moiety on the phenyl group
at the 2 position of the triazoloquinoxaline ring and the introduction of an acyl on the amino group
at the 4 position, are the characteristics that should confer affinity at the A3 AR. A mini-series of
compounds was developed using different linkers (chains from 2 to 12 atoms containing C, N and
O atoms) and fluorophores (e.g., BODIPY, Tamra and Cy5). The best compound of the series was
AV039 (50), which showed a pKD of about 9 at the human A3 AR and was more than 650-fold selective
over other receptor subtypes (Figure 14). This compound was able to specifically label the A3 AR in
cells containing a mixed population of ARs, thus it represented an ideal tool for the study of these
receptors [92,96].
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introduced using two linkers of different l ngths at the N1 or N10 positio s, in rd r to nvestigate
which position gives the best flexibility to the molecule, to best accommodate the orthosteric binding
site [101]. One compound (51) (Figure 14) showed an affinity of about 1 µM at the A1 AR and an IC50
value in the same range towards the A2B AR, and therefore was demonstrated to be a useful tool for
detecting these AR subtypes in fluorescence confocal microscopy experiments on cells.
5. Conclusions
From this review, it is clear that even if ARs were discovered more than forty years ago, their
complex mechanism of action, which includes, but is not limited to, activation, oligomerization and
internalization processes, is not fully elucidated. Over the last years, great progress in the field has
been obtained thanks to the advancements made in structural biology. AR probes were continuously
applied to new available techniques, which allowed deep investigation of the receptors, but at the
same time, obtained information that is useful for designing new, more specific, drugs and probes,
which in turn has contributed to the improvement in the AR research field. In particular, a better
understanding of the role and the mechanism of action of these receptors could allow design of more
specific therapies for several pathological conditions in which these receptors are involved, and for
that reason, ARs remain a very interesting and intriguing therapeutic target.
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